Windward Bio prices $175 million Nasdaq IPO

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Windward Bio priced a $175 million Nasdaq IPO, excluding the greenshoe option. * A concurrent $50 million private placement with Sanofi brings expected gross proceeds from both transactions to $225 million. * Novo Holdings invested in Windward in January 2025. * In September 2026, Windward reported positive interim asthma results for WIN378 and initiated Phase 3. * Windward develops ultra-long-acting antibodies for respiratory and dermatological diseases; lead candidate WIN378 is designed for twice-yearly dosing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings